Drugs / Ultratrace Iobenguane I 131
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00339131 | Jun 2006 → Jan 2007 | carcinoid tumor, paraganglioma, pheochromocytoma | Molecular Insight Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00992173 | Jan 2010 → Oct 2011 | neuroblastoma | Molecular Insight Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ultratrace iobenguane I 131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00339131 ↗ |
| Known as | MIBG | “Iobenguane, which is also known as MIBG, has been used in many patients who have types of cancers caused by what are known as neuroendocrine tumors” NCT00339131 ↗ |
| Route | Intravenous | “When administered intravenously, Iobenguane I 131 accumulates in the neuroblastoma cancer cells and causes them to die.” NCT00992173 ↗ |